S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:SYRS

Syros Pharmaceuticals (SYRS) Stock Forecast, Price & News

$3.98
+0.03 (+0.76%)
(As of 09/22/2023 ET)
Compare
Today's Range
$3.89
$4.03
50-Day Range
$3.35
$4.12
52-Week Range
$2.42
$6.95
Volume
42,810 shs
Average Volume
93,005 shs
Market Capitalization
$82.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

Syros Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
239.2% Upside
$13.50 Price Target
Short Interest
Healthy
3.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$31,436 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.41) to ($4.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

392nd out of 968 stocks

Pharmaceutical Preparations Industry

167th out of 445 stocks


SYRS stock logo

About Syros Pharmaceuticals (NASDAQ:SYRS) Stock

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

SYRS Price History

SYRS Stock News Headlines

Syros Pharmaceuticals (SYRS) Gets a Buy from H.C. Wainwright
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Q2 2023 Syros Pharmaceuticals Inc Earnings Call
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Syros Pharmaceuticals (NASDAQ: SYRS)
Q1 2023 Syros Pharmaceuticals Inc Earnings Call
See More Headlines
Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SYRS Company Calendar

Last Earnings
8/08/2023
Today
9/22/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYRS
Fax
N/A
Employees
117
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.50
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+241.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-94,650,000.00
Pretax Margin
-1,065.37%

Debt

Sales & Book Value

Annual Sales
$14.88 million
Book Value
$6.32 per share

Miscellaneous

Free Float
18,546,000
Market Cap
$81.80 million
Optionable
Optionable
Beta
1.59
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Nancy A. Simonian M.D. (Age 62)
    Pres, CEO & Director
    Comp: $955.39k
  • Dr. Richard A. Young Ph.D. (Age 69)
    Scientific Founder, Member of Scientific Advisory Board & Director
    Comp: $108.37k
  • Dr. Eric R. Olson Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $667.6k
  • Dr. David A. Roth M.D. (Age 60)
    Chief Medical Officer
    Comp: $679.52k
  • Dr. James E. Bradner M.D. (Age 51)
    Founder
  • Dr. Nathanael S. Gray Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Jason Haas (Age 55)
    Chief Financial Officer
  • Ms. Karen Hunady M.S.
    Director of Corp. Communications & Investor Relations
  • Mr. Gerald E. Quirk Esq. (Age 55)
    J.D., Chief Legal & Compliance Officer
  • Ms. Lisa Roberts
    VP of HR













SYRS Stock - Frequently Asked Questions

Should I buy or sell Syros Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SYRS shares.
View SYRS analyst ratings
or view top-rated stocks.

What is Syros Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 12 month price objectives for Syros Pharmaceuticals' shares. Their SYRS share price forecasts range from $11.00 to $15.00. On average, they anticipate the company's share price to reach $13.50 in the next year. This suggests a possible upside of 241.8% from the stock's current price.
View analysts price targets for SYRS
or view top-rated stocks among Wall Street analysts.

How have SYRS shares performed in 2023?

Syros Pharmaceuticals' stock was trading at $3.59 at the start of the year. Since then, SYRS stock has increased by 10.0% and is now trading at $3.95.
View the best growth stocks for 2023 here
.

When is Syros Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our SYRS earnings forecast
.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) posted its earnings results on Tuesday, August, 8th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by $0.19. The firm earned $2.83 million during the quarter, compared to analysts' expectations of $3.17 million.

When did Syros Pharmaceuticals' stock split?

Syros Pharmaceuticals's stock reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO?

3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Syros Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.02%), Geode Capital Management LLC (0.63%), ExodusPoint Capital Management LP (0.57%), LPL Financial LLC (0.46%), Shay Capital LLC (0.13%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David Roth, Eric R Olson, Richard A Young and Timothy Tyson.
View institutional ownership trends
.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $3.95.

How much money does Syros Pharmaceuticals make?

Syros Pharmaceuticals (NASDAQ:SYRS) has a market capitalization of $81.80 million and generates $14.88 million in revenue each year. The company earns $-94,650,000.00 in net income (profit) each year or ($5.53) on an earnings per share basis.

How many employees does Syros Pharmaceuticals have?

The company employs 117 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The official website for the company is www.syros.com. The company can be reached via phone at (617) 744-1340 or via email at hannahd@sternir.com.

This page (NASDAQ:SYRS) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -